



Biomarkers in the Prognosis of COVID-19 in the Emergency Department: May the Soluble Urokinase Plasminogen Activator Receptor (suPAR) Help?

Eduardo Esteban-Zubero^{1*} and Cristina García-Muro²

¹*Emergency Department, Hospital San Pedro, Logroño, Spain*

²*Department of Pediatrics, Hospital San Pedro, Logroño, Spain*

***Corresponding Author:** Eduardo Esteban-Zubero, Emergency Department, Hospital San Pedro, Logroño, Spain.

Received: August 19, 2020

Published: August 31, 2020

© All rights are reserved by **Eduardo Esteban-Zubero and Cristina García-Muro.**

Keywords: suPAR; Biomarkers; COVID-19; Pandemic

Abbreviations

suPAR: Soluble Urokinase-Type Plasminogen Activator Receptor; ED: Emergency Department; ALI: Acute Lung Injury; ARDS: Acute Respiratory Distress Syndrome; COPD: Chronic Obstructive Pulmonary Disease

The biomarker suPAR (soluble urokinase-type plasminogen activator receptor), discovered in 1992, is the soluble form of the cell membrane-bound protein uPAR, which is expressed primarily in immune cells, endothelial cells and smooth muscle cells. uPAR is released in inflammatory or activation processes of the immune system, therefore, in these situations, suPAR reflects the degree of immune activation in the subject [1].

Blood suPAR levels are stable during the day, being possible to be quantified in various biological fluids, including blood [2], plasma [3], urine [4], saliva [5], cerebrospinal fluid [6], ascitic fluid [7], and pleural fluid [8]. The normal level of suPAR in plasma is 2 - 3 ng/mL in healthy subjects, over 3 - 4 ng/mL in unselected patients in the Emergency Department (ED), and over 9 - 10 ng/mL in critically ill patients [9,10].

Several studies have shown that suPAR levels are associated with morbidity and mortality, being a negative predictor of several infectious diseases, including sepsis and pneumonia [11].

Because the elevation of suPAR is not specific to a single disease and may be associated with the coexistence of several pathologies simultaneously, its application as a prognostic and non-diagnostic marker could be useful. This property could be used for risk stratification in unselected patients [12].

In the Emergency Department there is a great renewal of patients, making it necessary to ensure optimal treatment and observation of all admitted patients. All of this must be based on a correct risk assessment in order to ensure that the most serious patients are prioritized in care and study under more careful observation. To improve the patient management in the ED, several biomarkers have been developed to support the physician. One of this is suPAR, revealing recent its utility as a risk stratifier [12].

New COVID-19 pandemic affected several patients worldwide. The pathological and clinical course of the most severe lung injuries induced by SARS-CoV-2 may be divided into three distinct phases. 1) Robust virus replication associated with fever, cough, myalgia, and other systemic symptoms that generally improve in a few days. 2) Progressive decline in virus titers, recurrence of fever, hypoxemia, and progression to pneumonia-like symptoms. 3) 20% of patients evolve to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which often results in death [13]. An excess of inflammatory response is observed [14].

Several authors also observed that disease progression is affected by comorbidities, including chronic obstructive pulmonary disease (COPD), diabetes, hypertension, and malignancy [15]. Literature reveals that suPAR levels are associated with morbidity and mortality in a large number of acute and chronic diseases (including cardiovascular, liver, kidney, and lung diseases). In fact, literature data suggested that suPAR levels in serum of patients with different pathologies are elevated (> 4 ng/ml), with good statistical significance [16].

Attending to the actual situation, where any specific biomarker has been developed to categorize the gravity of COVID-19 in the ED, suPAR may play a role as a COVID-19 prognostic marker and

Bibliography

1. Ploug M., *et al.* "A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria". *European Journal of Biochemistry* 208.2 (1992): 397-404.
2. Koch A., *et al.* "Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients". *Critical Care* 15.1 (2011): R63.
3. Ostrowski SR., *et al.* "High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients". *Journal of Acquired Immune Deficiency Syndromes* 39.1 (2005): 23-31.
4. Sier CF., *et al.* "Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance". *Laboratory Investigation* 79.6 (1999): 717-722.
5. Gustafsson A., *et al.* "Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels". *Biomarker Insights* 6 (2011): 119-125.
6. Ostergaard C., *et al.* "Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome". *Scandinavian Journal of Infectious Disease* 36.1 (2004): 14-19.
7. Sier CF., *et al.* "Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice". *Thrombosis and Haemostasis* 91.2 (2004): 403-411.
8. Ozsu S., *et al.* "Diagnostic value of suPAR in differentiating non-cardiac pleural effusions from cardiac pleural effusions". *The Clinical Respiratory Journal* 10.1 (2016): 61-66.
9. Donadello K., *et al.* "Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients". *Journal of Critical Care* 29.1 (2014): 144-149.
10. Haupt TH., *et al.* "Healthy lifestyles reduce suPAR and mortality in a Danish general population study". *Immunity and Ageing* 16 (2019): 1.
11. Huang Q., *et al.* "The Diagnostic and Prognostic Value of Supar in Patients With Sepsis: A Systematic Review and Meta-Analysis". *Shock* 53.4 (2020): 416-425.
12. Schultz M., *et al.* "Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial". *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine* 27.1 (2019): 43.
13. Peiris JSM., *et al.* "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study". *Lancet* 361 (2003): 1767-1772.
14. Channappanavar R., *et al.* "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology". *Seminars in Immunopathology* 39.5 (2017): 529-539.
15. Guan WJ., *et al.* "Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis". *European Respiratory Journal* 55.5 (2020): 2000547.

16. D'Alonzo D., *et al.* "COVID-19 and pneumonia: a role for the uPA/uPAR system". *Drug Discovery Today* 25.8 (2020): 1528-1534.
17. Chalkias A., *et al.* "Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients". *Molecular Diagnosis and Therapy*, (2020): 1-5.

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: www.actascientific.com/

Submit Article: www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667